Loading
A phase 2 trial of Toripalimab in non-small-cell lung cancer and small-cell lung cancer, run by Elpiscience (Suzhou) Biopharma, Ltd., now recruiting.
A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT06623136 by Elpiscience (Suzhou) Biopharma, Ltd., with 40 participants planned, started 2025-04-30 and due to reach its primary completion in 2027-02-28. Interventions recorded: ES102, Toripalimab. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Toripalimab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Toripalimab, Immune checkpoint inhibitors.
Shares Toripalimab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Toripalimab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Toripalimab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Toripalimab, Immune checkpoint inhibitors.
Shares Toripalimab, Immune checkpoint inhibitors.
Shares Toripalimab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/